{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:51Z","timestamp":1793242311366,"version":"4.5.0"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016332","name":"Medical Research Center Oulu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01-21-472"],"award-info":[{"award-number":["MRC-01-21-472"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semcancer.2021.12.003","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T12:09:15Z","timestamp":1639224555000},"page":"382-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"P3","title":["Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-0472","authenticated-orcid":false,"given":"Kalyani","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kuttikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Q.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-8744","authenticated-orcid":false,"given":"Fareed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Buddenkotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-6710","authenticated-orcid":false,"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2021.12.003_bib0005","series-title":"Cutaneous T-Cell Lymphoma","author":"Cloninc","year":"2021"},{"key":"10.1016\/j.semcancer.2021.12.003_bib0010","series-title":"Skin (cutaneous) T-cell Lymphoma","author":"Action","year":"2021"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cam4.472","article-title":"Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries","volume":"4","author":"Litvinov","year":"2015","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0025","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1365-4632.2010.04567.x","article-title":"Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006","volume":"49","author":"Alsaleh","year":"2010","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaad.2008.09.063","article-title":"Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides","volume":"60","author":"Sun","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0035","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.semcancer.2021.12.003_bib0040","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.12.003_bib0045","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"20","key":"10.1016\/j.semcancer.2021.12.003_bib0050","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.path.2014.02.006","article-title":"CD30-negative cutaneous T-Cell lymphomas other than mycosis fungoides","volume":"7","author":"Willemze","year":"2014","journal-title":"Surg. Pathol. Clin."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.hoc.2018.08.004","article-title":"Rare cutaneous T-Cell lymphomas","volume":"33","author":"Damasco","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.hoc.2019.04.004","article-title":"Overview of cutaneous T-Cell lymphomas","volume":"33","author":"Larocca","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-kappaB and nuclear factor of activated T cells pathways","volume":"182","author":"Perez","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clindermatol.2015.05.008","article-title":"Systemic involvement in mycosis fungoides","volume":"33","author":"Burg","year":"2015","journal-title":"Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"23","key":"10.1016\/j.semcancer.2021.12.003_bib0090","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0100","series-title":"Sezary Syndrome","author":"Vakiti","year":"2021"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and sezary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garcia-Diaz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0120","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2020001441","article-title":"Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma","volume":"4","author":"Iyer","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat. Genet."},{"issue":"26","key":"10.1016\/j.semcancer.2021.12.003_bib0130","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0135","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0140","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0145","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0150","article-title":"Epigenetics in the pathogenesis and treatment of cutaneous T-Cell lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0155","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0165","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semcancer.2021.12.003_bib0170","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.2019004725","article-title":"Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma","volume":"136","author":"Gaydosik","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.semcancer.2021.12.003_bib0175","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in Sezary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0180","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4161\/cbt.12.12.18144","article-title":"The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma","volume":"12","author":"Abraham","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0185","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2017-03-772996","article-title":"Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity","volume":"130","author":"Roelens","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/jid.2014.356","article-title":"CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","volume":"135","author":"Moins-Teisserenc","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cyto.b.21738","article-title":"Naive\/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: putative cell of origin overlaps disease classification","volume":"96","author":"Horna","year":"2019","journal-title":"Cytometry B Clin. Cytom."},{"issue":"18","key":"10.1016\/j.semcancer.2021.12.003_bib0200","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0205","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-18-4099","article-title":"Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma","volume":"25","author":"Hamrouni","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0210","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41375-020-01068-2","article-title":"Xenograft and cell culture models of Sezary syndrome reveal cell of origin diversity and subclonal heterogeneity","volume":"35","author":"Poglio","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.semcancer.2021.12.003_bib0215","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0220","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fcell.2020.00851","article-title":"Cellular interactions and inflammation in the pathogenesis of cutaneous T-Cell lymphoma","volume":"8","author":"Stolearenco","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/jid.2014.284","article-title":"Malignant T cells secrete galectins and induce epidermal hyperproliferation and disorganized stratification in a skin model of cutaneous T-cell lymphoma","volume":"135","author":"Thode","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0230","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1523-1747.2000.00995.x","article-title":"Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis","volume":"115","author":"Echchakir","year":"2000","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0240","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood.V91.11.4331","article-title":"Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma","volume":"91","author":"Bagot","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0245","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2133.2005.06755.x","article-title":"Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides","volume":"153","author":"Abeni","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"23","key":"10.1016\/j.semcancer.2021.12.003_bib0250","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","article-title":"CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior","volume":"19","author":"Vermeer","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0255","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1067\/mjd.2001.116345","article-title":"Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity","volume":"45","author":"Yoo","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0260","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(81)70021-5","article-title":"An unusual and fatal case of disseminated cutaneous herpes simplex. Infection in a patient with cutaneous T cell lymphoma (mycosis fungoides)","volume":"4","author":"Goldgeier","year":"1981","journal-title":"J. Am. Acad. Dermatol."},{"issue":"18","key":"10.1016\/j.semcancer.2021.12.003_bib0270","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood-2015-02-626432","article-title":"IL-13 as a novel growth factor in CTCL","volume":"125","author":"Wasik","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0275","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","article-title":"Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA","volume":"107","author":"Asadullah","year":"1996","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0280","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor microenvironment in mycosis fungoides and Sezary syndrome","volume":"28","author":"Rubio Gonzalez","year":"2016","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1346-8138.12305","article-title":"Immunological milieu in mycosis fungoides and Sezary syndrome","volume":"41","author":"Miyagaki","year":"2014","journal-title":"J. Dermatol."},{"issue":"14","key":"10.1016\/j.semcancer.2021.12.003_bib0300","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.semcancer.2021.12.003_bib0305","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-11-1192","article-title":"IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma","volume":"17","author":"Miyagaki","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0310","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0315","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.coi.2006.03.017","article-title":"Expanding the effector CD4 T-cell repertoire: the Th17 lineage","volume":"18","author":"Harrington","year":"2006","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0320","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/jid.2011.27","article-title":"Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat3 signaling pathway","volume":"131","author":"Krejsgaard","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0325","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0330","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V88.4.1383.bloodjournal8841383","article-title":"Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain)","volume":"88","author":"Dummer","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0335","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","article-title":"The immunopathogenesis of cutaneous T-cell lymphoma","volume":"9","author":"Rook","year":"1995","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"16","key":"10.1016\/j.semcancer.2021.12.003_bib0340","first-page":"4430","article-title":"Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies","volume":"54","author":"Tendler","year":"1994","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0345","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archderm.1993.01680250098016","article-title":"The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T cells","volume":"129","author":"Rook","year":"1993","journal-title":"Arch Dermatol"},{"issue":"18","key":"10.1016\/j.semcancer.2021.12.003_bib0350","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0355","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2008.224","article-title":"Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome","volume":"22","author":"Krejsgaard","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0360","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/10428194.2018.1516037","article-title":"IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model","volume":"60","author":"Wu","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"10.1016\/j.semcancer.2021.12.003_bib0365","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0370","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2326-6066.CIR-13-0199-T","article-title":"IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization","volume":"2","author":"Ohmatsu","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0375","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-021-08142-7","article-title":"Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma","volume":"21","author":"Mehdi","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0380","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/jid.2013.488","article-title":"The role of IL-32 in cutaneous T-cell lymphoma","volume":"134","author":"Suga","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib0385","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.4161\/cc.28256","article-title":"IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF)","volume":"13","author":"Willerslev-Olsen","year":"2014","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0390","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1046\/j.1365-2133.2001.04192.x","article-title":"Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"144","author":"Leroy","year":"2001","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0395","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1600-0625.2000.009004248.x","article-title":"IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression","volume":"9","author":"Asadullah","year":"2000","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0400","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V92.1.252.413k08_252_258","article-title":"Interleukin-15 is an autocrine\/paracrine viability factor for cutaneous T-cell lymphoma cells","volume":"92","author":"Dobbeling","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0405","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/2159-8290.CD-15-1297","article-title":"Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma","volume":"6","author":"Mishra","year":"2016","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0410","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3109\/10428194.2011.582202","article-title":"Synergistic enhancement of cellular immune responses by the novel Toll receptor 7\/8 agonist 3M-007 and interferon-gamma: implications for therapy of cutaneous T-cell lymphoma","volume":"52","author":"Wysocka","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"15\u201316","key":"10.1016\/j.semcancer.2021.12.003_bib0415","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.molimm.2011.07.008","article-title":"IFN-alpha primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity","volume":"48","author":"Hansen","year":"2011","journal-title":"Mol. Immunol."},{"issue":"13","key":"10.1016\/j.semcancer.2021.12.003_bib0420","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","article-title":"Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15","volume":"104","author":"Wysocka","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0425","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood.V98.9.2778","article-title":"Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells","volume":"98","author":"Qin","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0430","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2007-06-095182","article-title":"IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes","volume":"111","author":"Marzec","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0440","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1038\/bcj.2017.64","article-title":"Malignant T cells activate endothelial cells via IL-17 F","volume":"7","author":"Lauenborg","year":"2017","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0445","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2013-01-480889","article-title":"Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma","volume":"122","author":"Krejsgaard","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0450","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nm.3291","article-title":"An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy","volume":"19","author":"Chung","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0455","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/10428194.2014.919634","article-title":"CCR4+T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16","volume":"56","author":"Tuzova","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0460","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2013-09-527739","article-title":"MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma","volume":"123","author":"Ito","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0465","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0470","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0475","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: A new key player in dermatology and beyond","volume":"141","author":"Bagci","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0480","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"issue":"34","key":"10.1016\/j.semcancer.2021.12.003_bib0485","doi-asserted-by":"crossref","first-page":"36112","DOI":"10.1074\/jbc.M401122200","article-title":"Characterization of the signaling capacities of the novel gp130-like cytokine receptor","volume":"279","author":"Dreuw","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0490","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5582581","article-title":"IL-31 and IL-8 in cutaneous T-Cell lymphoma: looking for their role in itch","volume":"2021","author":"Abreu","year":"2021","journal-title":"Adv. Hematol."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0495","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0500","article-title":"Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants","volume":"26","author":"van Santen","year":"2021","journal-title":"Biochem. Biophys. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0505","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0510","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0515","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","article-title":"IL-12 reverses cytokine and immune abnormalities in Sezary syndrome","volume":"154","author":"Rook","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0520","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CDLI.6.1.79-84.1999","article-title":"Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma","volume":"6","author":"Lee","year":"1999","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0525","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2","article-title":"Human peripheral blood contains two distinct lineages of dendritic cells","volume":"29","author":"Robinson","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0530","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"46","key":"10.1016\/j.semcancer.2021.12.003_bib0535","doi-asserted-by":"crossref","first-page":"74592","DOI":"10.18632\/oncotarget.12816","article-title":"Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sezary syndrome","volume":"7","author":"Manfrere","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0540","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1468-3083.2012.04495.x","article-title":"Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis","volume":"27","author":"Miyagaki","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0545","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/jid.2011.470","article-title":"Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma","volume":"132","author":"Miyagaki","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0550","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/jid.2010.128","article-title":"Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma","volume":"130","author":"Miyagaki","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0555","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-1747.1998.00263.x","article-title":"Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas","volume":"111","author":"Tensen","year":"1998","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0560","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1074-7613(00)80455-0","article-title":"LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator","volume":"8","author":"Mauri","year":"1998","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0565","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.4049\/jimmunol.167.5.2479","article-title":"The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity","volume":"167","author":"Morel","year":"2001","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib0570","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.165.8.4397","article-title":"Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor","volume":"165","author":"Morel","year":"2000","journal-title":"J. Immunol."},{"issue":"5334","key":"10.1016\/j.semcancer.2021.12.003_bib0575","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1126\/science.277.5334.2005","article-title":"Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells","volume":"277","author":"Sallusto","year":"1997","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0580","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1084\/jem.185.12.2171","article-title":"Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes","volume":"185","author":"Forssmann","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0585","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3389\/fonc.2019.00907","article-title":"Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-Cell lymphoma","volume":"9","author":"Tanita","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0590","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ajpath.2011.05.040","article-title":"Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma","volume":"179","author":"Gunther","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0595","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L","article-title":"Dendritic cells as a major source of macrophage-derived chemokine\/CCL22 in vitro and in vivo","volume":"31","author":"Vulcano","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0600","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124233","article-title":"Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma","volume":"4","author":"Vieyra-Garcia","year":"2019","journal-title":"JCI Insight"},{"issue":"21","key":"10.1016\/j.semcancer.2021.12.003_bib0605","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","article-title":"Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma","volume":"76","author":"Takahashi","year":"2016","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0610","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jaci.2007.01.003","article-title":"Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells","volume":"119","author":"Ebner","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0615","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0620","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1172\/JCI58978","article-title":"Periostin promotes chronic allergic inflammation in response to Th2 cytokines","volume":"122","author":"Masuoka","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0625","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2230.2008.02990.x","article-title":"Increased serum thymic stromal lymphopoietin levels in patients with cutaneous T cell lymphoma","volume":"34","author":"Miyagaki","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2021.12.003_bib0630","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.2584","article-title":"Cutaneous lymphomas-An update 2019","volume":"37","author":"Kempf","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0635","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting Cancer immune control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0640","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.28551","article-title":"CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta","volume":"134","author":"Jablonska","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0645","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0650","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/jid.2009.45","article-title":"Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors","volume":"129","author":"Wu","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0655","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ni.f.213","article-title":"Orchestrating the orchestrators: chemokines in control of T cell traffic","volume":"9","author":"Bromley","year":"2008","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0660","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.187.6.875","article-title":"Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes","volume":"187","author":"Sallusto","year":"1998","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0665","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1189\/jlb.1105633","article-title":"Chemokines, chemokine receptors, and cancer metastasis","volume":"79","author":"Kakinuma","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0670","article-title":"Pathophysiology of chemokines and chemokine receptors in dermatological science: a focus on psoriasis and cutaneous T-cell lymphoma","volume":"30","author":"Lee CH","year":"2012","journal-title":"Dermatol. Sin."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0675","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.yadr.2005.04.001","article-title":"Chemokines and inflammatory skin diseases","volume":"21","author":"Homey","year":"2005","journal-title":"Adv. Dermatol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0680","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1084\/jem.194.10.1541","article-title":"CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin","volume":"194","author":"Reiss","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib0685","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0690","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1607-551X(09)70019-1","article-title":"Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines","volume":"24","author":"Wu","year":"2008","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0695","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1046\/j.1523-1747.2003.12555.x","article-title":"Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides","volume":"121","author":"Kallinich","year":"2003","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0700","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","article-title":"Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides","volume":"48","author":"Kakinuma","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0705","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1309\/3N7P-J84L-JQ9K-G89R","article-title":"The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides","volume":"115","author":"Lu","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0710","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.semcancer.2021.12.003_bib0715","doi-asserted-by":"crossref","first-page":"29839","DOI":"10.1074\/jbc.M103106200","article-title":"Kinetic investigation of chemokine truncation by CD26\/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family","volume":"276","author":"Lambeir","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0720","first-page":"139","article-title":"[Studies about the values of polycyclic aromatic hydrocarbons in oils used in production of plant protective agents]","volume":"43","author":"Maslowska","year":"1992","journal-title":"Rocz. Panstw. Zakl. Hig."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0725","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"Forster","year":"1999","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0730","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2133.2004.06325.x","article-title":"Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7","volume":"152","author":"Sokolowska-Wojdylo","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0735","first-page":"16","article-title":"Deregulated signalling and inflammation in cutaneous T-cell lymphoma","volume":"182","author":"Odum","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0740","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in t cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0745","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fphys.2019.00500","article-title":"The JAK\/STAT pathway in skeletal muscle pathophysiology","volume":"10","author":"Moresi","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0750","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"5332","key":"10.1016\/j.semcancer.2021.12.003_bib0755","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"issue":"Pt 8","key":"10.1016\/j.semcancer.2021.12.003_bib0760","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell. Sci."},{"issue":"5573","key":"10.1016\/j.semcancer.2021.12.003_bib0765","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A road map for those who don\u2019t know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"issue":"1-2","key":"10.1016\/j.semcancer.2021.12.003_bib0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0775","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.semcancer.2021.12.003_bib0780","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"\u201cDo We Know Jack\u201d About JAK? A Closer Look at JAK\/STAT Signaling Pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front. Oncol."},{"issue":"6127","key":"10.1016\/j.semcancer.2021.12.003_bib0785","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0790","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111711","article-title":"STAT3 dysregulation in mature t and NK cell lymphomas","volume":"11","author":"Seffens","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.semcancer.2021.12.003_bib0795","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0800","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.jid.5701246","article-title":"Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells","volume":"128","author":"van Kester","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0805","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401415","article-title":"Inhibition of constitutively activated Stat3 correlates with altered Bcl-2\/Bax expression and induction of apoptosis in mycosis fungoides tumor cells","volume":"13","author":"Nielsen","year":"1999","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.semcancer.2021.12.003_bib0810","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0815","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.163.7.4073","article-title":"Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4","volume":"163","author":"Showe","year":"1999","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0820","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.12299","article-title":"Genetic markers associated with progression in early mycosis fungoides","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib0825","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.1996.tb52680.x","article-title":"The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma","volume":"795","author":"Rook","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0830","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0835","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0840","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0845","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.0022-202x.2001.01436.x","article-title":"Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells","volume":"117","author":"Qin","year":"2001","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0850","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/jid.2011.293","article-title":"Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome","volume":"132","author":"van der Fits","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0855","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.leu.2402093","article-title":"Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells","volume":"15","author":"Eriksen","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0860","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/jid.2010.349","article-title":"MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome","volume":"131","author":"van der Fits","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0865","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","article-title":"Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma","volume":"20","author":"Krejsgaard","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0870","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2403610","article-title":"Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha","volume":"19","author":"Brender","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0875","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V97.4.1056","article-title":"STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma","volume":"97","author":"Brender","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib0880","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.18632\/oncotarget.6916","article-title":"Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma","volume":"7","author":"Ikeda","year":"2016","journal-title":"Oncotarget"},{"issue":"29","key":"10.1016\/j.semcancer.2021.12.003_bib0885","doi-asserted-by":"crossref","first-page":"45730","DOI":"10.18632\/oncotarget.10160","article-title":"STAT5 induces miR-21 expression in cutaneous T cell lymphoma","volume":"7","author":"Lindahl","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.semcancer.2021.12.003_bib0890","doi-asserted-by":"crossref","first-page":"20555","DOI":"10.18632\/oncotarget.4111","article-title":"Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma","volume":"6","author":"Sibbesen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2021.12.003_bib0895","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0900","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0905","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020280","article-title":"JAK3 is expressed in the nucleus of malignant t cells in cutaneous t cell lymphoma (CTCL)","volume":"13","author":"Vadivel","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0910","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1182\/blood-2005-08-007377","article-title":"STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes","volume":"108","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.12.003_bib0915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13148-018-0450-y","article-title":"Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma","volume":"10","author":"Hervouet","year":"2018","journal-title":"Clin. Epigenetics"},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib0920","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","article-title":"Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter","volume":"157","author":"Zhang","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib0925","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","volume":"127","author":"Willerslev-Olsen","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.semcancer.2021.12.003_bib0930","doi-asserted-by":"crossref","first-page":"34201","DOI":"10.18632\/oncotarget.9077","article-title":"Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma","volume":"7","author":"Ehrentraut","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib0935","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"Perez","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0940","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0945","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1600-0625.2010.01102.x","article-title":"Cutaneous T-cell lymphoma cells are sensitive to rapamycin","volume":"19","author":"Kremer","year":"2010","journal-title":"Exp. Dermatol."},{"issue":"30","key":"10.1016\/j.semcancer.2021.12.003_bib0950","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/onc.2015.462","article-title":"Oncogenic PTEN functions and models in T-cell malignancies","volume":"35","author":"Tesio","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib0955","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/leu.2009.223","article-title":"Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways","volume":"24","author":"Zhao","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib0960","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41375-018-0305-8","article-title":"Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance","volume":"33","author":"Cristofoletti","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.semcancer.2021.12.003_bib0965","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.1158\/0008-5472.CAN-09-2367","article-title":"Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays","volume":"69","author":"Caprini","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib0970","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib0975","first-page":"265","article-title":"Transformation of cutaneous T cell lymphoma to large cell lymphoma","volume":"132","author":"Salhany","year":"1988","journal-title":"A clinicopathologic and immunologic study, Am J Pathol"},{"issue":"25","key":"10.1016\/j.semcancer.2021.12.003_bib0980","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis--tracing the accessory","volume":"33","author":"Borsig","year":"2014","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib0985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024667","article-title":"Involvement of mTOR in CXCL12 mediated T cell signaling and migration","volume":"6","author":"Munk","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib0990","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2013.04.027","article-title":"A comprehensive immunohistochemical approach of AKT\/mTOR pathway and p-STAT3 in mycosis fungoides","volume":"69","author":"Levidou","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5945","key":"10.1016\/j.semcancer.2021.12.003_bib0995","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.1173569","article-title":"Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a","volume":"325","author":"Fine","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1000","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41598-018-36810-5","article-title":"Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib1005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/exd.12547","article-title":"In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features","volume":"23","author":"Papadavid","year":"2014","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029541","article-title":"miR-122 regulates p53\/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma","volume":"7","author":"Manfe","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2021.12.003_bib1015","article-title":"NF-kappaB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib1020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"issue":"13","key":"10.1016\/j.semcancer.2021.12.003_bib1035","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1073\/pnas.0400885101","article-title":"Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation","volume":"101","author":"Schmidt-Supprian","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib1040","first-page":"433","article-title":"NFkappaB function and regulation in cutaneous T-cell lymphoma","volume":"3","author":"Chang","year":"2013","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib1045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-065X.2011.01091.x","article-title":"Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors","volume":"246","author":"Smale","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib1060","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib1065","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/0008-5472.CAN-08-3221","article-title":"Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma","volume":"69","author":"Kiessling","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib1070","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.4049\/jimmunol.176.9.5652","article-title":"STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice","volume":"176","author":"Cho","year":"2006","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.semcancer.2021.12.003_bib1075","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1074\/jbc.273.22.14008","article-title":"Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates","volume":"273","author":"Giri","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib1080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archdermatol.2010.376","article-title":"Reduction of Fas\/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma","volume":"147","author":"Wu","year":"2011","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2016.00382","article-title":"Checkpoint of t cell functions in multiple sclerosis","volume":"7","author":"Volpe","year":"2016","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib1090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(00)80275-7","article-title":"Fas modulation of apoptosis during negative selection of thymocytes","volume":"5","author":"Castro","year":"1996","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.semcancer.2021.12.003_bib1095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nri2570","article-title":"CD95, BIM and T cell homeostasis","volume":"9","author":"Bouillet","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib1100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/jid.2008.309","article-title":"Low FAS\/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation","volume":"129","author":"Wu","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib1105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.abb.2010.10.020","article-title":"Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL)","volume":"508","author":"Wu","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"issue":"36","key":"10.1016\/j.semcancer.2021.12.003_bib1110","doi-asserted-by":"crossref","first-page":"26041","DOI":"10.1074\/jbc.M602222200","article-title":"NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages","volume":"281","author":"Cao","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib1115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1600-0609.1997.tb00970.x","article-title":"Activation of the interleukin-10 gene in the human T lymphoma line HuT 78: identification and characterization of NF-kappa B binding sites in the regulatory region of the interleukin-10 gene","volume":"59","author":"Mori","year":"1997","journal-title":"Eur. J. Haematol."},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2021.12.003_bib1120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199609054800","article-title":"The involvement of the candidate proto-oncogene NFKB2\/lyt-10 in lymphoid malignancies","volume":"23","author":"Neri","year":"1996","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib1125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ni824","article-title":"A requirement for CARMA1 in TCR-induced NF-kappa B activation","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.12.003_bib1130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2011.101","article-title":"Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome","volume":"25","author":"Braun","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib1135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2009.05.007","article-title":"The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology","volume":"30","author":"Vereecke","year":"2009","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.12.003_bib1140","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41375-018-0066-4","article-title":"Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma","volume":"32","author":"Gallardo","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib1145","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib1150","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1084\/jem.20160579","article-title":"The scaffolding function of the RLTPR protein explains its essential role for CD28 co-stimulation in mouse and human T cells","volume":"213","author":"Roncagalli","year":"2016","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib1155","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib1160","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","article-title":"Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation","volume":"81","author":"Kyriakis","year":"2001","journal-title":"Physiol. Rev."},{"issue":"21","key":"10.1016\/j.semcancer.2021.12.003_bib1165","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1016\/j.febslet.2006.08.025","article-title":"Functions of the MAPK family in vertebrate-development","volume":"580","author":"Krens","year":"2006","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib1170","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1021\/cr000241p","article-title":"MAP kinases","volume":"101","author":"Chen","year":"2001","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib1175","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/MCB.19.4.2435","article-title":"Mitogen-activated protein kinases: specific messages from ubiquitous messengers","volume":"19","author":"Schaeffer","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"22","key":"10.1016\/j.semcancer.2021.12.003_bib1180","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib1185","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood-2010-09-305128","article-title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS\/RAF\/MEK signaling cascade","volume":"117","author":"Kiessling","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2021.12.003_bib1190","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-07-1005","article-title":"Targeting Ras in myeloid leukemias","volume":"14","author":"Braun","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib1195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-020-00380-5","article-title":"Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features","volume":"10","author":"Argyropoulos","year":"2020","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib1200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/jid.2014.367","article-title":"Identification of p38beta as a therapeutic target for the treatment of Sezary syndrome","volume":"135","author":"Bliss-Moreau","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"20","key":"10.1016\/j.semcancer.2021.12.003_bib1205","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2021.12.003_bib1210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hon.2850","article-title":"Cutaneous T-cell lymphomas-An update 2021","volume":"39","author":"Kempf","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"5 Suppl 1","key":"10.1016\/j.semcancer.2021.12.003_bib1215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1590\/abd1806-4841.20175634","article-title":"Folliculotropic mycosis fungoides: challenging clinical, histopathological and immunohistochemical diagnosis","volume":"92","author":"Malveira","year":"2017","journal-title":"An. Bras. Dermatol."},{"issue":"12","key":"10.1016\/j.semcancer.2021.12.003_bib1220","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1468-3083.2012.04513.x","article-title":"Granulomatous slack skin disease: a review, in comparison with mycosis fungoides","volume":"26","author":"Shah","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1225","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjd.13832","volume":"173","author":"Klemke","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1346-8138.12328","article-title":"Skin manifestations of adult T-cell leukemia\/lymphoma: clinical, cytological and immunological features","volume":"41","author":"Tokura","year":"2014","journal-title":"J. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib1235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0019-5154.96201","article-title":"Adult T-cell leukemia\/lymphoma: a retroviral malady","volume":"57","author":"Khader","year":"2012","journal-title":"Indian J. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12788\/j.sder.2018.001","article-title":"Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Kempf","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1245","series-title":"Subcutaneous Panniculitis Like T-cell Lymphoma","author":"Musick","year":"2021"},{"issue":"2","key":"10.1016\/j.semcancer.2021.12.003_bib1250","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2009.02.035","article-title":"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma","volume":"62","author":"Gormley","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.12.003_bib1255","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1203475417715209","article-title":"Primary cutaneous CD4(+) Small\/Medium pleomorphic T-Cell lymphoproliferative disorder: a case series","volume":"21","author":"Maurelli","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"issue":"11","key":"10.1016\/j.semcancer.2021.12.003_bib1260","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.5858\/arpa.2017-0230-RA","article-title":"Primary cutaneous acral CD8(+) T-Cell lymphoma","volume":"141","author":"Hathuc","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1265","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/627401","article-title":"Extranodal natural-killer\/t-cell lymphoma, nasal type","volume":"2010","author":"Gill","year":"2010","journal-title":"Adv. Hematol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.12.003_bib1270","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-07-2403","article-title":"Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells","volume":"68","author":"Marzec","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2021.12.003_bib1275","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0014-5793(92)80909-Z","article-title":"Interleukin-8, a chemotactic and inflammatory cytokine","volume":"307","author":"Baggiolini","year":"1992","journal-title":"FEBS Lett."},{"issue":"21","key":"10.1016\/j.semcancer.2021.12.003_bib1280","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1158\/1078-0432.CCR-14-0707","article-title":"Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function","volume":"20","author":"Wolk","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2021.12.003_bib1285","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","article-title":"Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-Cell lymphoma","volume":"138","author":"Fanok","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.12.003_bib1290","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/039463201002300304","article-title":"IL-31 a Th2 cytokine involved in immunity and inflammation","volume":"23","author":"Castellani","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.semcancer.2021.12.003_bib1295","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-010-9464-8","article-title":"Interleukin-16 as a marker of S\u00e9zary Syndrome onset and stage","author":"Richmond","year":"2011","journal-title":"J Clin Immunol"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:11:25Z","timestamp":1760919085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":259,"alternative-id":["S1044579X21002960"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.12.003","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}